Daiichi Sankyo, a major pharmaceutical company, has applied to the Ministry of Health, Labor and Welfare for approval of a new coronavirus vaccine under development.
It is a messenger RNA vaccine similar to Pfizer and others, and it is the first time that a domestic pharmaceutical company has applied for approval of this type of vaccine.
Daiichi Sankyo announced on the 13th that it has applied for approval to the Ministry of Health, Labor and Welfare for the new corona mRNA vaccine it has been developing.
This vaccine is a mechanism that induces an immune response by administering an artificially created genetic material, mRNA, so that part of the spike protein, which serves as a foothold when the virus infects cells in the body, is created.
It contains ingredients that correspond to the conventional new coronavirus that initially spread, and is intended to be used as the third vaccination for those over the age of 18.
In a final-stage clinical trial that assumed a third dose of about 5,000 people over the age of 18, it was confirmed that it was as effective as the Pfizer and Moderna vaccines, and that there was no problem with safety. increase.
This is the second application for approval of a new corona vaccine developed by a domestic pharmaceutical company, following Shionogi's "recombinant protein vaccine".
Daiichi Sankyo commented, "We will continue to develop vaccines for Omicron strains. We would like to contribute to the safety and security of society and the protection of people's health by promptly providing domestically produced vaccines."